The authors respond to correspondence from Peng Luo and colleagues regarding their original article on satricabtagene autoleucel (satri-cel) treatment in gastric cancer. They emphasize that comments on the dynamic nature of claudin‑18.2 (CLDN18.2) protein expression are warranted. They report that the changing expression of CLDN18.2 in tumor cells and the biological heterogeneity of the tumor pose an important problem for targeted therapy. These factors can affect how well a tumor responds to tumor antigen-targeted therapy. The authors agree that this is a broader challenge in the field of therapies targeting specific tumor antigens. They do not mention any new numerical data or specific statistics in the text. They do not describe the new results of the study either, but focus on responding to expert comments on their original article.